Cell shape, and not 2D migration, predicts extracellular matrix-driven 3D cell invasion in breast cancer

• Main Authors: Janani P. Baskaran, Anna Weldy, Justinne Guarin, Gabrielle Munoz, Polina H. Shpilker, Michael Kotlik, Nandita Subbiah, Andrew Wishart, Yifan Peng, Miles A. Miller, Lenore Cowen, Madeleine J. Oudin
• Format: Article
• Language: English
• Published: AIP Publishing LLC 2020-06-01
• Series: APL Bioengineering
• Online Access: http://dx.doi.org/10.1063/1.5143779

Metastasis, the leading cause of death in cancer patients, requires the invasion of tumor cells through the stroma in response to migratory cues, in part provided by the extracellular matrix (ECM). Recent advances in proteomics have led to the identification of hundreds of ECM proteins, which are more abundant in tumors relative to healthy tissue. Our goal was to develop a pipeline to easily predict which ECM proteins are more likely to have an effect on cancer invasion and metastasis. We evaluated the effect of four ECM proteins upregulated in breast tumor tissue in multiple human breast cancer cell lines in three assays. There was no linear relationship between cell adhesion to ECM proteins and ECM-driven 2D cell migration speed, persistence, or 3D invasion. We then used classifiers and partial-least squares regression analysis to identify which metrics best predicted ECM-driven 2D migration and 3D invasion responses. We find that ECM-driven 2D cell migration speed or persistence did not predict 3D invasion in response to the same cue. However, cell adhesion, and in particular cell elongation and shape irregularity, accurately predicted the magnitude of ECM-driven 2D migration and 3D invasion. Our models successfully predicted the effect of novel ECM proteins in a cell-line specific manner. Overall, our studies identify the cell morphological features that determine 3D invasion responses to individual ECM proteins. This platform will help provide insight into the functional role of ECM proteins abundant in tumor tissue and help prioritize strategies for targeting tumor-ECM interactions to treat metastasis.